Last reviewed · How we verify

Cuprimine — Competitive Intelligence Brief

Cuprimine (PENICILLAMINE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antirheumatic Agent [EPC]. Area: Immunology.

marketed Antirheumatic Agent [EPC] Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Cuprimine (PENICILLAMINE) — Valeant Pharms Intl.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cuprimine TARGET PENICILLAMINE Valeant Pharms Intl marketed Antirheumatic Agent [EPC] 1970-01-01
Arava LEFLUNOMIDE Sanofi marketed Antirheumatic Agent [EPC] Cytochrome P450 1A2 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antirheumatic Agent [EPC] class)

  1. Sanofi · 1 drug in this class
  2. Valeant Pharms Intl · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cuprimine — Competitive Intelligence Brief. https://druglandscape.com/ci/penicillamine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: